Arcutis Biotherapeutics Inc Stock News

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)s share price hit a new 52-week low during trading on Friday . The company traded as low as $16.09 and last traded at $16.28, with a volume of 5407 shares. The stock had previously closed at $17.73. A number of brokerages have recently commented on ARQT. Mizuho reiterated a buy rating []

MetLife Investment Management LLC increased its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) by 27.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,548 shares of the companys stock after acquiring an additional 2,304 shares during the period. MetLife Investment Management LLCs []

Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target cut by investment analysts at Morgan Stanley from $50.00 to $35.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 85.77% from the stock’s […]

Arcutis Biotherapeutics (NASDAQ:ARQT) and Mirati Therapeutics (NASDAQ:MRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Valuation and Earnings This table compares Arcutis Biotherapeutics and Mirati Therapeutics top-line revenue, earnings per share []

WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immun

WESTLAKE VILLAGE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) --   Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in i

WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu

WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu

Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?

WESTLAKE VILLAGE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immu

WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to addr

WESTLAKE VILLAGE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- In order to address a major limitation of today's most widely used method for gauging severity of plaque psoriasis (the PASI scale), Arcutis

WESTLAKE VILLAGE, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to addres

Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.

WESTLAKE VILLAGE, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), today announced its decision to terminate the recently initiated Phase 2a clinical trial eva